Fabry disease (FD) (MIM#301500) is considered as inborn error of glycosphingolipid metabolism due to reduce to null catalytic activity of the acid hydrolase α-galactosidase A (α-Gal A) (EC 3.2.1.22), which results in the accumulation of globotriaosylceramide (Gb3), globotriaosylsphingosine (lyso-Gb3), and other glycosphingolipids (such as galabiosylceramide, Gb2, etc.)in different tissues [1]. Here, GABBR2 is linked to Fabry disease.